Recently, two independent research groups identified the previously uncharacterized chemokine-like factor-like MARVEL transmembrane domain containing 6 (CMTM6) as a critical regulator of PD-L1 in a broad range of cancer cells and discovered that CMTM6 inhibits the ubiquitination of PD-L1 and its subsequent degradation via lysosomes, promoting stabilization of PD-L1 in the plasma membrane [25,26]. This evidence concerns the gene CMTM6 and cancer.